Mer­ck still on the hunt for bil­lion-dol­lar deals, cit­ing Prometheus and Dai­ichi Sankyo as ex­am­ples

Mer­ck is still in pur­suit of deals of a sim­i­lar size and scope to the com­pa­ny’s ac­qui­si­tions of Prometheus Bio­sciences and Ac­celeron, and is will­ing to pay up to $15 bil­lion.

It’s al­so still con­sid­er­ing small­er deals and col­lab­o­ra­tions.

Dur­ing Thurs­day’s fourth-quar­ter earn­ings call, Mer­ck CEO Rob Davis out­lined his views on the drug­mak­er’s port­fo­lio, say­ing he feels good about its progress but he con­tin­ues to “be­lieve we need more.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER